1 of 1
Story summary
- Emcure Pharmaceuticals will cut the price of Poviztra, a semaglutide injection, by 55% to Rs 3,999 per month, effective April 3, 2026.
- The change aims to improve access to obesity treatment for 254 million people in India affected by obesity.
- Emcure is the first Indian company to exclusively distribute Poviztra.
- Concurrently, Novo Nordisk is reducing prices for Ozempic and Wegovy to enhance accessibility and strengthen its market position in India.
